Please note that this special conference will take place as an in-person event in Boston and will not live-stream content for virtual participation. The conference content will be recorded and made available as an on-demand program after the conference.

CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

Sunday, September 15

• Welcome and Opening Keynote Lecture

monday, September 16

• Plenary Session 1: Cachexia, Diet, and Metabolism
• Plenary Session 2: Immunology and Immunotherapy
• Plenary Session 3: Stromal Aspects of the Microenvironment and Tumor Microenvironment

tuesday, September 17

• Plenary Session 4: KRAS Resistance, Mechanisms, and Therapeutics
• Plenary Session 5: KRAS Cell Biology
• Plenary Session 6: Lymphoma Epigenetics
• Plenary Session 7: Tumor Cell Biology

wednesdayday, September 18

• Plenary Session 8: Plasticity
• Plenary Session 9: Metabolism
• Debate: Have We Learned Anything from the KRAS Inhibitors That We Didn’t Already Know from Mice?

REGISTRATION
3-8 P.M.

WELCOME AND Keynote lectures
5:30-7:15 P.M.
CME-Eligible

• Keynote Lecture
  Eileen M. O’Reilly, Memorial Sloan Kettering Cancer Center, New York, New York
• Rising Star Keynote
  Joseph D. Mancias, Dana-Farber Cancer Institute, Boston, Massachusetts

Lightning Presentation Session A
7:15-7:35 P.M.
CME-Eligible

POSTER SESSION A AND OPENING RECEPTION
7:45-9:45 P.M.

CONTINENTAL BREAKFAST
7-8 A.M.

Plenary Session 1: Cachexia, Diet, and Metabolism
8:15-10 A.M.
CME-Eligible

• Mechanisms of pancreatic cancer cachexia
  Teresa A. Zimmers, Oregon Health & Science University Knight Cancer Institute, Portland, Oregon
• Developing therapies for pancreatic cancer cachexia
  Andrew E. Hendifar, Cedars Sinai Medical Center, Los Angeles, California
• Tobias Janowitz, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

Short talks selected from proffered abstracts

break
10-10:30 A.M.

PLENARY SESSION 2: Immunology and Immunotherapy
10:30 a.m.-12:15 p.m.
CME-Eligible

• The tumor-reactive CD8+ T-cell repertoire in pancreatic cancer as revealed by single-cell sequencing
  Rienk Offringa, German Cancer Research Center, Heidelberg, Germany
• Investigating the role of CD4 T cells in the pancreatic tumor microenvironment
  Katelyn T. Byrne, Oregon Health and Science University, Portland, Oregon
• Exploiting functional specialization of myeloid-derived suppressor cells to overcome therapeutic resistance in pancreatic cancer
  Jashodeep Datta, University of Miami Miller School of Medicine, Miami, Florida

Short talks selected from proffered abstracts

Free time/lunch on own
12:15-2:30 p.m.

Plenary Session 3: Stromal Aspects of the Microenvironment and Tumor Microenvironment
2:30-4:15 p.m.
CME-Eligible

• Mechanisms and consequences of pancreatic cancer stromal evolution
  Mara Sherman, Memorial Sloan Kettering Cancer Center, New York, New York

Additional speakers to be announced
Short talks selected from proffered abstracts

lightning presentation b
4:15-4:35 P.M.

Poster session b/reception
4:45-6:45 P.m.

CONTINENTAL BREAKFAST
7-8 A.M.

Plenary Session 4: KRAS Resistance, Mechanisms, and Therapeutics
8:15-10 A.M.
CME-Eligible

• Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer
  Andrew Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts
• Adaptation and resistance to pan-RAS inhibition in pancreatic ductal adenocarcinoma
  Kenneth P. Olive, Columbia University Irving Medical Center, New York, New York
• Targeting the oncogenic state of RAS with tri-complex inhibitors
  Mallika Singh, Revolution Medicines, Redwood City, California

Short talks selected from proffered abstracts

break
10-10:30 A.M.

Plenary Session 5: KRAS Cell Biology
10:30 a.m.-12:30 p.m.
CME-Eligible

• Targeting KRAS for pancreatic cancer treatment
  Channing Der, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
• Piro Lito, Memorial Sloan Kettering Cancer Center, New York, New York
• Elucidation of metabolic resistance mechanisms to RAS inhibition
  Kirsten Bryant, University of North Carolina, Chapel Hill, North Carolina
• Christopher M. Counter, Duke University School of Medicine, Durham, North Carolina

Short talks selected from proffered abstracts

Free time/lunch on own
12:30-2:45 p.m.

Plenary Session 6: Early Detection and Interception of Precursor Lesions
2:45-4:30 P.M.
CME-Eligible

• Peter J. Allen, Duke University School of Medicine, Durham, North Carolina
• Multimodal tools for noninvasive cancer monitoring
  Erica D. Pratt, Boston University, Boston, Massachusetts
• Improving pancreatic cancer early detection using a tumor marker gene test
  Michael G. Goggins, Johns Hopkins University, Baltimore, Maryland

Short talks selected from proffered abstracts

Break
4:30-4:50 P.M.

Plenary Session 7: tumor cell biology
4:50-6:25 P.M.
CME-Eligible

• Targeting Syndecan1 in pancreatic cancer
  Wantong Yao, The University of Texas MD Anderson Cancer Center, Houston, Texas
• Metabolic adaptations to autophagy inhibition
  Christina Towers, The Salk Institute for Biological Studies, La Jolla, California

Additional speakers to be announced
Short talks selected from proffered abstracts

lightning presentation session c
6:30-6:50 p.m.

poster session c/reception
7-9 p.m.

CONTINENTAL BREAKFAST
7-8 A.M.

Plenary Session 8: plasticity
8-10 a.m.
CME-Eligible

• Stephanie K. Dougan, Dana-Farber Cancer Institute, Boston, Massachusetts
• Regulation of tumor and stromal cell plasticity by metabolic stress
  Cosimo Commisso, Sanford Burnham Prebys, San Diego, California
• Christine Chio, Columbia University, New York, New York
• Nicholas T. Woods, University of Nebraska Medical Center, Omaha, Nebraska

break
10-10:20 A.M.

Plenary Session 9: metabolism
10:20 A.M.-12:20 p.m.
CME-Eligible

• Alec C. Kimmelman, NYU Langone Health, New York, New York
• Systemic metabolic networks in pancreatic cancer and associated cachexia
  Nada Kaalany, Harvard Medical School / Boston Children’s Hospital, Boston, Massachusetts
• Metabolic competition in pancreatic tumor microenvironment regulates innate immune responses
  Kamiya Mehla, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Additional speakers to be announced

debate: Have We Learned Anything from the KRAS Inhibitors That We Didn’t Already Know from Mice?
12:30-1:15 p.m.
CME-Eligible

Departure
1:15 p.m.